NVAX - Novavax Operating income before deduction of amortization

Graphic logo of Novavax (NVAX)

Novavax, Inc. (NVAX) overcame the crisis by stabilizing expenses under the leadership of John Jacobs. The EBITDA_Co valuation visualizes this balance, where the value of 0.00 serves as the current metric. The company relies on manufacturing outsourcing while retaining its patents, and diversification through protein-based vaccines for influenza and COVID-19 expands its market reach.

NVAX - Novavax Corp Operating profit before deduction of amortization over the range 11/23/2025 - 11/12/2026

Summary analytical data breakdowns for Novavax (NVAX)

- stock price and consensus target price:
Price Chart Novavax Pharma|NVAX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Novavax|NVAX - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Novavax|NVAX - Company Net Assets|Market Capitalization to Book Value Ratio novavax.com|NVAX - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Coefficient Novavax, Inc.|NVAX - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Novavax Inc|NVAX - Company Debts|Debts to Book Value Novavax|NVAX - Company Long-Term Liabilities|Company Short-Term Debt Novavax|Quick Ratio novavax.com
- earnings and market ratios statistics:
NVAX - Net Income|Expected Profit Novavax, Inc.|NVAX - P/E Multiple|Forward P/E Multiple novavax.com|NVAX - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Novavax|NVAX - Operating profit before deduction of amortization|Earnings per share for the trailing year Novavax|NVAX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months novavax.com|NVAX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Novavax, Inc.
Analysis of all company metrics:Novavax, Inc.
Signature product of Novavax Pharma

A business's ability to withstand market downturns depends directly on the generation of real cash flow. The partnership with Sanofi and cost optimization at Novavax, Inc. (NVAX) are currently establishing a foundation for financial stability. This level of EBITDA measures the actual cash generated by operations before debt payments. Growth in this metric confirms the effectiveness of expense management. Stable dynamics here minimize the issuer's default risk.

Competitor analysis for Novavax, Inc.

Gilead Corp - Profit before payment of interest, taxes and amortization|Cidara Therapeutics, Inc. - Operating profit EBITDA|Operating income before deduction of amortization curevac.com CVAC|Valneva (VALN) - Profit before payment of interest, taxes and amortization|Vir Biotechnology Inc - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization SIGA|Operating profit EBITDA Emergent Bio|Profit before payment of interest, taxes and amortization Atea Pharmaceuticals (AVIR)|Operating income before deduction of amortization invivyd.com|Profit before payment of interest, taxes and amortization Enanta Pharmaceuticals, Inc. ENTA|INO: Operating profit before amortization|HLVX - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Kalaris Tx|DYAI (dyadic.com) - Operating profit before deduction of amortization|NNVC (NanoViricides) - Profit before payment of interest, taxes and amortization|TLPH (Talphera) - Operating profit EBITDA|Operating profit EBITDA Cocrystal Pharma Inc|Operating profit before deduction of amortization TRAW (Traws Pharma, Inc.)|Profit before payment of interest, taxes and amortization DWTX (dwtx.com)|Operating profit EBITDA QLGN (Qualigen Therapeutics)|Operating profit EBITDA AlloVir Inc ALVR|VBIV: Operating profit before deduction of amortization|VIRI (Virios Therapeutics) - Operating profit before amortization|VXRT (vaxart.com) - Operating profit before deduction of amortization